2021
Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021
Paltiel AD, Schwartz JL. Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021. Annals Of Internal Medicine 2021, 174: m21-2965. PMID: 34461034, PMCID: PMC8422997, DOI: 10.7326/m21-2965.Peer-Reviewed Original ResearchConceptsVaccine effectivenessVaccination coverageAsymptomatic testingBroad vaccination coverageLess frequent testingCOVID-19 prevention strategiesHigh vaccination ratesBase-case assumptionsFall 2021COVID-19 incidenceUnvaccinated personsVaccination ratesDisease progressionHypothetical cohortEffective vaccineAsymptomatic transmissionPrevention strategiesViral transmissionCumulative casesNonpharmaceutical interventionsDrug abuseCumulative infectionsSafe returnVaccinePopulation coverage
2014
A Marginal Benefit Approach for Vaccinating Influenza “Superspreaders”
Skene KJ, Paltiel AD, Shim E, Galvani AP. A Marginal Benefit Approach for Vaccinating Influenza “Superspreaders”. Medical Decision Making 2014, 34: 536-549. PMID: 24740238, PMCID: PMC4209160, DOI: 10.1177/0272989x14523502.Peer-Reviewed Original ResearchConceptsHerd immunity thresholdSeasonal influenza epidemicsVaccination coverageSeasonal influenzaVaccination strategiesEpidemiological findingsImmunity thresholdHerd immunityInfluenza epidemicsVaccination changesPotential superspreadersSimplified transmission modelVaccinationTarget populationIntervention designEpidemicInfluenzaInterventionTransmission modelCost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania.
Fitzpatrick MC, Hampson K, Cleaveland S, Mzimbiri I, Lankester F, Lembo T, Meyers LA, Paltiel AD, Galvani AP. Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania. Annals Of Internal Medicine 2014, 160: 91-100. PMID: 24592494, PMCID: PMC4084874, DOI: 10.7326/m13-0542.Peer-Reviewed Original ResearchConceptsVaccination campaignCanine vaccinationPrompt postexposure prophylaxisBase-case analysisVaccination coverageHuman rabiesSocietal willingnessProbability-based evaluationU.S. dollarsEconomic outcomesContact-tracing studiesEmpirical uncertaintyRural AfricaRural TanzaniaOptimal vaccination coverageOngoing vaccination campaignRabies vaccination campaignsGreat uncertaintyAnnual mortality ratePostexposure prophylaxisEpidemiologic variablesTransmission of rabiesHealth burdenWillingnessMortality rate
2013
Dengue dynamics and vaccine cost-effectiveness in Brazil
Durham DP, Mbah M, Medlock J, Luz PM, Meyers LA, Paltiel AD, Galvani AP. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine 2013, 31: 3957-3961. PMID: 23791696, PMCID: PMC3755607, DOI: 10.1016/j.vaccine.2013.06.036.Peer-Reviewed Original ResearchConceptsVaccination costsDengue vaccine trialsVaccine efficacyTotal vaccination costDengue vaccinationCost-effectiveness analysisPotential vaccination policiesVaccine trialsPay thresholdsVaccine efficacy scenariosOptimal allocationLow vaccine efficacyLatest clinical trialsOptimistic scenarioTrial estimatesVaccination coverageEfficacy scenariosClinical trialsAvailable dosesVaccination policyFurther trialsVaccination modelHerd immunityVaccinationCost
2007
Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries
Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, Paltiel AD. Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 78-90. PMID: 17589368, PMCID: PMC3570247, DOI: 10.1097/qai.0b013e31812506fd.Peer-Reviewed Original ResearchConceptsEffective HIV vaccineHIV prevalenceHIV vaccineCondom useHIV infectionRisk behaviorsFuture HIV prevalenceTotal HIV infectionsHeterosexual HIV epidemicSuccessful vaccination campaignsRisk behavior changeVaccination statusMiddle-income countriesVaccinated individualsVaccination coverageDisease stageVaccine efficacyHIV epidemicVaccination scenariosVaccination campaignHigh riskAdult populationVaccinePrevalenceInfection